REVEAL - Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 204 participants.
Also called NCT06788535
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase
- Phase 3
- Enrolled
- 204 participants
- Sponsor
- Registry
-
NCT06788535
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT06788535. Allocation not applicable; no masking; primary purpose diagnostic. Start 2025-01-14 (actual); primary completion 2026-04-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- REVEAL - Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis
- Acronym
- REVEAL
- Condition
- Cardiac Amyloidosis
- Intervention (Drug)
- I-124 evuzamitide
- Lead sponsor
- Sharmila Dorbala
- Collaborator
- Bayer
Record details
- Record id
cardio:ct-nct06788535- Content hash
f6250999f3f8481c5db2ae5a27049c4857b117edd979220719551618ab38bb56